A phase II, single arm, prospective study of neoadjuvant sutent for patients with renal cell carcinoma.
Phase of Trial: Phase II
Latest Information Update: 10 Dec 2013
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 12 May 2011 Planned End Date changed from 1 Jan 2011 to 1 Jan 2013 as reported by ClinicalTrials.gov.
- 26 Jan 2010 Planned end date changed from 1 Jan 2010 to 1 Jan 2011 as reported by ClinicalTrials.gov.